Thank so call. quarter TransMedics afternoon first much everyone you Brian. earnings and to XXXX welcome Good
Joining me Officer. Chief Stephen Gordon, our is today Financial
we discussed on year will that our XXXX we As previous for call, a believe commercial transformative be adoption. TransMedics
total footprint leveraging results QX We transplant meaningfully potential, technology Our started Program strong to validate Heart our year. i.e. the our OCS National the commercial NOP Liver, growth our leveraging OCS platforms, our the in and as well strong or further throughout year-over-year sales conviction net of year QX and the results as with same QX period Lung, unique our was revenue. speak expand three momentum XX% $XX.X XX% growth representing XXXX. for year-over-year $XX.X themselves. representing XXX% growth were over and We XXXX. XXX% million, approximately U.S. growth million $X.X, revenue and of representing achieved for revenue million, International XX% growth QX over
our few we positive trends very expand in trajectory. by encouraged confidence our Importantly, are that commercial commercial
you. these trends with Let me share
predominantly driven very while bulk This centers each market. of to in First, two strong, for Oregon growth was important revenue approximately by revenue the was reasons. our five QX seven is
Oregon drive surface always programs to it wider. the getting significant the the of Two, of markets, transplant grow OCS our opportunity future then opportunity First, focus penetration new we technology. volume programs that potential shows first deep are been of three deep with added This high and OCS go the key technology. demonstrates the growth to has transplant by potential it rapid leaving commercial to across only scratching our
revenue U.S., QX. sales liver transplantation of the the given our procedures in -- in second U.S. liver was trend share relative The as represented of the expected, largest we volumes
volumes volume combined. is reminder, a total the and transplant lung liver double heart U.S. As nearly the
the The majority case QX and that truly order. trend revenue, vast was third not fact stocking real-time that utilization of represented the
high by to impact it to due explain we due trend trend contribution of on is are States. business NOP We're linear excited this Let its the closely This in and making to overall why. monitoring more and me the our the revenue United predictable. mix
of critical acquisition. commercial overall the and quarter. the National rather and NOP, our the is role already X-X, growth cases, a QX In now The approximately case in from growth direct this With represents a revenue U.S. played during and our programs. last penetration NOP, new has our or driving efforts, NOP than Program revenue of U.S. OCS trend portion volume in existing significant into XX%, deeper came transplant revenue important perhaps most
heart On per and organ lung was NOP, NOP. was XX% NOP, basis, the liver XX% XX% was
we see all expect grow organ percentage to to revenue from to forward, we As continue three the of NOP move platforms. across
resources typical to Importantly, ability our NOP this operational of early us with at more momentum the and significantly the repeatedly while reduced for sales OCS logistics, enabled facilitate technology. demonstrate shortening friction central volume level, with to cycle transparent
me it order clinical go installation explain. wanting adopt OCS. the of their initial to how to XX and team be days scheduling buy-in first any days, and transplant would of Historically, center the take on Let additional to direct model, between waiting from the somewhere it first of to to there, From the XX us to take trained acquisition XXX for to purchase they XX via of buy-in back, this used issuance used revenue days until days -- and and opposite. operate first We few within the administrative from it's leadership in case. many days OCS. true centers the did see to somewhere complete first XX the saw program. live XX With clinician QX of the it And until case clinical we then going NOP, initial between generating transplant -- take once they're by the few literally training
hours. NOP more the In and experienced also the coming volumes the they NOP above, catalyst fact, literally of growth only was transplant drives on we see in U.S. From there, cases. kept the not our for center back six commercial once case the simplicity it but significant as starting in most quickest the penetration, growth overall XXXX. as model, volume center efficiency for Based
also expect addition to catalysts to NOP, year. In from two this additional benefit we
is were in and new recent the case ahead came This DCD U.S. approval OCS the centers a allow platform. expand Heart This into and not that growth trial. original grow will heart centers our of schedule. ultimately of approval indication part FDA to for our First, DCD OCS in revenue the us will the drive that of
number center market. each the active of Second, expansion the for of OCS organ
as the NOP QX. and organ; routinely their to is goal centers seen end heart Our lung, liver XX using we've are in XXXX in to XX OCS for centers transplants that per with the
shift let's you goals goals our on operational Now, actual an for provide XXXX, the to update our progress to operation. related against
buttress headcount time to and the launching by contract to surgical while points First, full the NOP program. surgeons NOP XX our bringing clinical regions. XX in In or our new expanding two goal staff, surgeon added total QX, was surgeons we NOP supported the
additional We expect XXXX. surgeons add to throughout
for our staff year XX beginning cross-trained OCS all in QX increased of being at U.S., whom the support also the XX to the from of are three We clinical of platforms. all across end the
by launch at U.S. the the we're geographical active NOP our us broad XX launch points XX of from in regions to at today, XXXX end United expanded coverage of and of territory. or States, points XX the as the end we of QX giving Finally,
our expand to was goal manufacturing infrastructure operational and capacity. Second,
inventory to derisk strategic and raw our production raw material our performance to negative goal to and year QX. business invest mid proud expand impact raw bolstering our macro of of XXXX. by any further to the in The chain impacts are meet This the plan headwinds. clinical help on XXXX execution challenges very execution the maintaining We've minimize We are and year. investments demand our continue supply make the of end in inventory to to this the throughout in year, operational We potential focused anticipated commercial supply chain volume track growing on commercial capacity in clinical was on to from we demand us demand. our process. level accommodate QX despite invested to of We're long-term material will material our last throughout in targeted meet
discuss potential these headwinds. Let's
transplant were lung they First, vulnerable volume further as QX. early waves somewhat the COVID in remains to
on from Although and we've no impact seen liver volumes. heart transplant Omicron minimal or
chain potential exposed remain ongoing we The is to supply headwind challenges. global second
adoption the While mitigated the the largely meaningfully our negatively are Despite that we in OCS increased technology, clinical results, to Nonetheless, usage. rate always inventory key have XXXX. we in impact QX area reviewed, and has and the impact of is rapid that for long-term control we strong our outlook. our an and to-date, catalysts may our cannot this mid, early our near, just revenue increasingly investments, demand have growing confident other us given
in above. our prudent headwinds remain global However, given we to potential need expectations mentioned the
million the annual represents previous are such full million XXXX. $XX million. XX and to year XXXX between to for our guidance, we our to As XX% $XX to between $XX million. This a a -- and over over XXX% solid $XX growth raising range compares This guidance revenue arrange
or here provide call of Lung of ISHLT, the place I Lung highlights took OCS over in turning Society would Before week's Transplantation the results meeting were and trials that from annual and to presented. where long-term Stephen, Heart summary the Boston, to like last of Heart International
receive successful in results at in the lead years, XX% DCD be of criteria for use of rates heart arm thus or procedure. using the heart in high trial And going seminal to OCS one showed year DCD heart standard XX% the cold OCS with of transplantation. in data and utilization reported lifesaving are -- of hearts OCS, our two-year control transplantation resulted transplanted significantly results respectively, by donor results, investigator. trial U.S., to one the for results importantly, with the the DCD and These survival U.S. compared storage. the expanding more XX%, clinical failure Heart access two Specifically, presented providing technology randomized the the in post-transplant instrumental donor of heart DCD to and that to DCD of hearts excellent patients utilization both Heart of was XX% The transplant
year's from routine results the the the criteria five lung now extended is resulted Stephen. transplant transplant U.S. lung will Lung routine on lead trial survival I in can to expand the by The OCS a With use five lung national investigator. call front, in have U.S. Lung and to turn in to that the the the outcome transplantation Lung in criteria of outcomes of XX% average the data. transplant five-year showed and compared that, good donor lung clinical favorably clinically show the outcomes that powerful lungs expand we compares U.S. volume based This from UNOS/OPTN On post-transplant over presented national of results OCS the DCD to the also XX% lungs US DBD were or that extended year
